Kyverna Therapeutics (KYTX) Payables (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Payables data on file, last reported at $11.6 million in Q1 2026.

• Quarterly Payables rose 36.96% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (up 36.96% YoY) and the FY2025 annual result came in at $5.3 million, up 14.75% from the prior year.
• Payables improved to $11.6 million in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $11.6 million in Q1 2026 to a low of $3.0 million in Q3 2025.
• A 4-year average of $7.0 million and a median of $6.4 million in 2024 frame the typical range for Payables.
• The widest YoY moves for Payables: up 104.01% in 2025, down 69.63% in 2025.
• Tracing KYTX's Payables over 4 years: stood at $4.4 million in 2023, then advanced by 6.1% to $4.6 million in 2024, then advanced by 14.75% to $5.3 million in 2025, then soared by 118.68% to $11.6 million in 2026.
• The last three Payables figures came in at $11.6 million (Q1 2026), $5.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.